Tag: Clarametyx Biosciences

Clarametyx Biosciences has filed a notice of an exempt offering of securities to raise $33,124,959.00 in New Equity Investment.

Clarametyx Biosciences has filed a notice of an exempt offering of securities to raise $33,124,959.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Clarametyx Biosciences is raising up to $33,124,959.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Richards played a…

Read More Read More

Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections

Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections

Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections January 05, 2024 10:06 AM Eastern Standard Time COLUMBUS, Ohio–(BUSINESS WIRE)–Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling…

Read More Read More